News

CorWave has announced that it has successfully completed a preclinical in vivo study of its implantable heart pump system.

The company has developed an implantable left ventricular assist device (LVAD) powered by its innovative wave membrane technology. The in vivo trials showed the pump’s effective operation over a six-month period. Additionally, the company reported the successful implantation of the device in nine chronic ovine models for 60 days, without the need for chronic anticoagulant therapy.

Based in Clichy, France, CorWave stated that there were no device failures or signs of thrombosis at the time of explant. The pump functioned in pulsatile mode, synchronizing with the heart’s natural rhythm. The studies also confirmed the device’s thromboresistance, stable algorithm, and hemocompatibility.

CorWave indicated that these results represent the final phase of its preclinical development, clearing the way for a first-in-human trial. The pump’s mechanism, coupled with an intelligent algorithm, adjusts its flow in response to the patient’s activity level, helping to maintain physiological balance, minimize adverse events, and enhance overall quality of life.

Dr. Martin Strueber, a cardiac surgeon, said in a news release that the technology could “shape the future of long-term mechanical circulatory support.” Strueber suggests that it could address the current limitations of rotary blood pumps and pave the way for truly smart and adaptive circulatory support.

“These results not only meet the highest standards in the LVAD industry but also indicate potential clinical advantages over rotary blood pumps that have been in use since the late 1990s. Following these significant milestones, the team is now actively preparing for the clinical introduction of the device,” said Louis de Lillers, CEO.


© CorWave